A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
/in Breast Cancer, Colorectal Cancer, Dendritic Cells, International Publications, Ovarian Cancer, Pancreatic Cancer /von 1999-06-01 / Clin. Cancer Res. 1999 Jun;5(6):1331-8Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 1999-05-05 / JAMA 1999 May;281(17):1588-9Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells
/in Hyperthermia, International Publications /von 1999-04-01 / J. Immunol. 1999 Apr;162(7):3757-60For the clinical application of thermochemotherapy given at mild temperatures
/in Hyperthermia, International Publications /von 1999-03-01 / Int J Hyperthermia 1999 Mar-Apr;15(2):79-107Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells
/in Dendritic Cells, Hypernephroma, International Publications /von 1999-03-01 / J. Urol. 1999 Mar;161(3):777-82Tumor stimulator cell modification by infection with Newcastle Disease Virus: analysis of effects and mechanism in MLTC-CML cultures
/in International Publications, Newcastle Disease Virus /von 1999-02-01 / Int. J. Oncol. 1999 Feb;14(2):205-15[Hyperthermia in combination with chemotherapy in gynecological cancers]
/in Hyperthermia, International Publications /von 1999-01-09 / Ned Tijdschr Geneeskd 1999 Jan;143(2):85-8A pilot study of melphalan, tumor necrosis factor-alpha and 41.8 degrees C whole-body hyperthermia
/in Hyperthermia, International Publications /von 1999-01-01 / Cancer Chemother. Pharmacol. 1999;43(5):409-14Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus
/in International Publications, Newcastle Disease Virus /von 1999-01-01 / Gene Ther. 1999 Jan;6(1):63-73
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de